Enanta Pharmaceuticals, Inc.
ENTA
$8.53
-$0.12-1.39%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 19.38% | -1.59% | 22.67% | -27.21% | 27.28% |
| Total Depreciation and Amortization | 0.58% | 35.32% | 85.59% | -19.36% | -4.35% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -61.51% | 30.22% | -48.90% | 91.12% | -13.03% |
| Change in Net Operating Assets | 1,430.90% | 1,767.26% | -98.77% | 240.04% | 180.52% |
| Cash from Operations | 229.79% | 19.72% | -61.55% | 29.61% | 48.34% |
| Capital Expenditure | 93.89% | 70.98% | 2.30% | -36.82% | -292.21% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,337.90% | -102.36% | 177.08% | 14,125.38% | -99.67% |
| Cash from Investing | -506.16% | -106.34% | 261.26% | 400.60% | -110.82% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -100.00% | 38.24% | 142.86% | -45.10% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 6.72% | -35.57% | 30.25% | -9.11% | -3.25% |
| Cash from Financing | 6.72% | -38.13% | 30.89% | -8.55% | -3.63% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 37.76% | -152.52% | 3,131.55% | 105.25% | -217.61% |